There is a U shaped association between non high density lipoprotein cholesterol with overall and cardiovascular mortality in chronic kidney disease stage 3–5

• Published in: Scientific reports Vol. 10; no. 1; p. 12749
• Main Authors: Chiu, Hsuan, Wu, Pei-Yu, Huang, Jiun-Chi, Tu, Hung-Pin, Lin, Ming-Yen, Chen, Szu-Chia, Chang, Jer-Ming
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 29.07.2020; Nature Publishing Group
• Subjects: 692/4022; 692/53; Aged; Biomarkers - blood; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - mortality; Cholesterol; Cholesterol - blood; Cholesterol, HDL; Cholesterol, LDL - blood; Dialysis; Dyslipidemia; Dyslipidemias - blood; Female; Follow-Up Studies; Glomerular Filtration Rate; Health risks; High density lipoprotein; Humanities and Social Sciences; Humans; Kidney diseases; Kidneys; Male; Metabolic disorders; Middle Aged; Mortality; multidisciplinary; Proportional Hazards Models; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - mortality; Risk Factors; Science; Science (multidisciplinary); Treatment Outcome; Triglycerides - blood
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-69794-2

Dyslipidemia is common in patients with chronic kidney disease (CKD), however the relationship between dyslipidemia and mortality in patients with moderate to severe CKD remains controversial. Non-high-density lipoprotein (HDL) cholesterol has been reported to be a more accurate predictor of clinical outcomes than conventional lipid measurements. Hence, the aim of this study was to investigate associations between non-HDL cholesterol and the risk of overall and cardiovascular mortality in patients with CKD stage 3–5. We enrolled 429 pre-dialysis patients with stage 3 to 5 CKD from May 2006 to January 2010. The patients were divided into four groups according to quartiles of non-HDL cholesterol. The patients were followed until death or until January 2020. During a median 11.6 years of follow-up, there were 78 (18.2%) deaths overall and 32 (7.5%) cardiovascular deaths. In adjusted models, the patients in quartile 1 (hazard ratio [HR] 3.368; 95% confidence interval [CI] 1.388–8.176; p  = 0.007), quartile 3 (HR 3.666; 95% CI 1.486–9.044; p  = 0.005), and quartile 4 (HR 2.868; 95% CI 1.136–7.240; p  = 0.026) of non-HDL cholesterol had a higher risk of overall mortality (vs. quartile 2). In addition, the patients in quartile 1 (HR 19.503; 95% CI 2.185–174.0925 p  = 0.008), quartile 3 (HR 28.702; 95% CI 2.990–275.559; p  = 0.004), and quartile 4 (HR 11.136; 95% CI 1.126–110.108; p  = 0.039) had a higher risk of cardiovascular mortality (vs. quartile 2). Our study showed a U-shaped relationship between non-HDL cholesterol and the risk of overall and cardiovascular mortality in patients with CKD stage 3–5. Assessing non-HDL cholesterol may help to identify subjects at high-risk of adverse outcomes.